We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PCSK9 Inhibitor

News List

AstraZeneca acquires Dogma Therapeutics’ PCSK9 inhibitor programme pharmaceutical-technology
September 18, 2020
AstraZeneca has signed an agreement to purchase a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed amount.
Amgen cuts US price of cholesterol drug by 60% pharmaphorum
December 20, 2018
Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year.
Repatha receives EC approval for new 420 mg single-dose delivery option cphi-online
February 24, 2017
Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.
US appeals court allows Sanofi, Regeneron to continue selling PCSK9 inhibitor Praluent firstwordpharma
February 10, 2017
Sanofi and Regeneron Pharmaceuticals announced that the US Court of Appeals for the Federal Circuit suspended a permanent injunction on Praluent (alirocumab) pending the companies' appeal.